Brain metastases: vizsgálatok itt: Kína
56 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleHippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 74
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07505173 - 3. fázisTaking peopleAnlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 134
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07443397 - 2. fázisNot yet taking people in KínaLimertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 45
- Run by
- The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07413952 - 2. fázisTaking peopleStudy on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 39
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07396454 - No phaseCsak meghívásosRetrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 380
- Run by
- Ming Yang
See details and how to joinNCT07373951 - 2. fázisNot yet taking people in KínaFurmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07365410 - 2. fázisNot yet taking people in KínaSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 45
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07343479 - 3. fázisTaking peopleFSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 258
- Run by
- Sun Yat-Sen University Cancer Center
See details and how to joinNCT07058428 - No phaseTaking peopleEvaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 100
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07251868 - 2. fázisTaking peopleElimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 168
- Run by
- Sun Yat-sen University
See details and how to joinNCT06582940 - No phaseTaking peopleAI-assisted Diagnosis of Malignant Brain Tumors
- Where
- Hangzhou
- Életkor
- 18 év to 100 év
- People
- 3000
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07198256 - 1/2. fázisTaking peopleA Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- Where
- Chongqing, Jinan, Shanghai
- Életkor
- 18 év to 89 év
- People
- 130 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06907043 - No phaseTaking peopleExploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- QIAO LI
See details and how to joinNCT07117864 - No phaseTaking peopleReal-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 100
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07008287 - 1/2. fázisTaking peopleUTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
- Where
- Changsha
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT05535413 - 2. fázisTaking peopleA Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 146
- Run by
- Henan Cancer Hospital
See details and how to joinNCT06945705 - 1/2. fázisTaking peopleStudy of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 74
- Run by
- Fudan University
See details and how to joinNCT06718933 - 2. fázisNot yet taking people in KínaHeterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 50
- Run by
- Fudan University
See details and how to joinNCT06797622 - 2. fázisTaking peopleAdebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 30
- Run by
- Beijing 302 Hospital
See details and how to joinNCT06418594 - 2. fázisTaking peopleCadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
- Where
- Changsha
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Rongrong Zhou
See details and how to joinNCT06702826 - No phaseTaking peopleAI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 800
- Run by
- Fudan University
See details and how to joinNCT06604689 - 2. fázisNot yet taking people in KínaA Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
- Where
- Guangzhou
- People
- 55
- Run by
- Sun Yat-sen University
See details and how to joinNCT06684873 - 1/2. fázisTaking peopleTIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06640582 - 2. fázisTaking peopleCranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 54
- Run by
- Fudan University
See details and how to joinNCT06501391 - No phaseTaking peopleSRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
- Where
- Lianyungang
- Életkor
- 18 év to 80 év
- People
- 46
- Run by
- The First People's Hospital of Lianyungang
See details and how to joinNCT06476093